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CASE REPORT Open Access
Metabolic therapy with PEG-arginase
induces a sustained complete remission in
immunotherapy-resistant melanoma
Carmela De Santo1†, Paul Cheng2†, Andrew Beggs3, Sharon Egan4, Alberto Bessudo5 and Francis Mussai1*
Abstract
Background: Metastatic melanoma is an aggressive skin cancer with a poor prognosis. Current treatment strategies
for high-stage melanoma are based around the use of immunotherapy with immune checkpoint inhibitors such as
anti-PDL1 or anti-CTLA4 antibodies to stimulate anti-cancer T cell responses, yet a number of patients will relapse
and die of disease. Here, we report the first sustained complete remission in a patient with metastatic melanoma
who failed two immunotherapy strategies, by targeting tumour arginine metabolism.
Case presentation: A 65-year-old patient with metastatic melanoma who progressed through two immunotherapy
strategies with immune checkpoint inhibitor antibodies was enrolled in a phase I study (NCT02285101) and treated
with 2 mg/kg intravenously, weekly pegylated recombinant arginase (BCT-100). The patient experienced no
toxicities > grade 2 and entered a complete remission which is sustained for over 30 months. RNA-sequencing
identified a number of transcriptomic pathway alterations compared to control samples. The tumour had absent
expression of the recycling enzymes argininosuccinate synthetase (ASS) and ornithine transcarbamylase (OTC)
indicating a state of arginine auxotrophy, which was reconfirmed by immunohistochemistry, and validation in a
larger cohort of melanoma tumour samples.
Conclusions: Targeting arginine metabolism with therapeutic arginase in arginine auxotrophic melanoma can be
an effective salvage for the treatment of patients who fail immunotherapy.
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Background
Melanoma is an aggressive skin malignancy with in-
creasing incidence, particularly among young adults.
The identification of metastatic disease in lymph nodes
or viscera at diagnosis is a poor prognostic factor [1].
Melanoma is well recognised as having a unique inter-
action with the immune response, both in terms of
mechanisms of immune escape but also as a source of
novel target antigens for the development of immune
therapies [2]. Current treatment strategies for high-stage
melanoma are based around the use of immunotherapy
with immune checkpoint inhibitors such as anti-PDL1
or anti-CTLA4 antibodies to stimulate anti-cancer T cell
responses, or signal-transduction inhibitors such as
those targeting BRAF and MEK pathways [3, 4]. Despite
these approaches, significant numbers of patients will
still relapse and die of disease within 5 years [5]. There-
fore, new strategies which target a different aspect of
melanoma biology are needed.
Arginine is a semi-essential amino acid that is catabo-
lised by tumour cell arginase I (ARGI) and II (ARGII)
enzymes and nitric oxide synthetase (NOS2) into metab-
olites essential for cell proliferation, protein production
and cell signalling [6]. However, defects in the expres-
sion of the arginine recycling enzymes ornithine trans-
carbamylase (OTC) and argininosuccinate synthetase
(ASS) can result in a dependence of cancer cells on
extracellular sources of arginine for survival [7].
The PEGylated recombinant human arginase, BCT-
100, catabolises arginine into ornithine and urea [8].
Therapeutic administration leads to a systemic depletion
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of arginine in the blood and tissues providing a new ap-
proach to target cancer metabolism [9]. BCT-100 has
shown safety and activity in patients treated with ad-
vanced hepatocellular carcinoma in early phase clinical
trials [10]. Grade 3 serious adverse events (SAE) attribut-
able to BCT-100 in these liver patients were limited to
transaminitis or tumour pain in up to 15% of patients.
Preclinical studies support the rationale for recombinant
arginase therapy in melanoma; however, targeting argin-
ine metabolism has not yet been considered an approach
after failure of immunotherapy [11]. Here, we report a
durable complete response by BCT-100 Arginase, in a
patient with multiple recurrent melanoma lesions.
Case presentation
A 65-year-old Caucasian male, a cigarette smoker of 50
pack-years, presented with dysphasia. A computed tom-
ography (CT) revealed two 2 cm lesions in the left par-
ietal lobe and bilateral enlarged axillary lymph nodes,
with multiple pleural infiltrates in both lung apices, dia-
phragms and mediastinum. The patient previously had
multiple pigmented skin lesions excised which were re-
ported to be malignant. The brain lesions were com-
pletely excised and found to be vimentin and S100
positive on immunohistochemistry, confirming the diag-
nosis of malignant melanoma. The patient had no ac-
tionable BRAF V600E mutations (wild-type).
The patient was initially treated with anti-CTLA4 anti-
body (Ipilimumab) for 3 months achieving a best response
of stable disease, before progression of his chest lesions.
He was then treated with anti-PDL1 antibody (pembroli-
zumab) for 2 months. The best response attained was a
partial response; however, he went on to develop increas-
ing pleural and axillary disease (Fig. 1a). Following a 3-
month wash-out period, the patient consented to the
clinical trial of BCT-100 therapy (NCT02285101).
Arginase (BCT-100) therapy was initiated at the
established Recommended Phase II Dose (2 mg/kg
intravenously weekly) that induces a persistent deple-
tion in systemic arginine to < 8 μM. CT evaluation
(week 13) revealed a partial response in all pleural-
based lesions and therapy was continued. Restaging
20 weeks after the first dose of BCT-100 dramatically
revealed a complete remission with clearance of all
pleural-based and axillary disease. Thirty months from
commencement of BCT-100, the patient remains on
weekly dosing and in radiologically confirmed
complete remission at all sites of disease (Fig. 1b).
BCT-100 has been well tolerated with the patient ex-
periencing only nausea, skin rash and diarrhoea,
which were not deemed drug-related. He had no dys-
phasia since excision of the brain lesions. He con-
tinues to tolerate treatment with no SAEs greater
than grade II.
Tumour tissue from the relapse surgery was evaluated
by RNA-sequencing and compared to a control dataset
obtained from the Genetic Expression Omnibus
(GSE20156). Volcano plot shows significant differential
expression between the melanoma patient treated and
the control cohort (Fig. 1c). The 30 top differentially
expressed genes are shown in Fig. 1d. Specific analysis of
the arginine metabolic pathway identified that the
tumour had relatively higher expression of arginase II
catabolic enzyme to control melanomas. Expression of
the recycling enzymes ASS and OTC expression were
extremely low in all samples (Fig. 1e). Immunohisto-
chemistry confirmed the almost complete absence of
ASS and OTC enzymes, consistent with a state of argin-
ine auxotrophy that defines sensitivity to arginase ther-
apy (Fig. 1f ). Interrogation of a further 44 samples of
metastatic melanomas held with the R2: Genomics Ana-
lysis and Visualization Platform (http://r2.amc.nl) con-
firms the majority of tumours have lower OTC than
ASS expression (Fig. 1g).
Discussion and conclusions
This is the first report of a complete response in a meta-
static melanoma patient treated with arginine deprivation
therapy, notably in the setting of prior immunotherapy
failure. The activity of PEGylated recombinant arginase
has been reported to inhibit melanoma proliferation in S
and G2/M phase and induce apoptosis in in vitro. Growth
of melanoma cell line xenografts was significantly inhib-
ited [11]. Among other tumour types, BCT-100 has dem-
onstrated preclinical activity, and clinical responses have
been seen in two clinical trials in adults with advanced he-
patocellular carcinoma (HCC) [9, 10, 12]. The patient ex-
perienced no drug limiting toxicity or immunogenicity
even after more than 2 years of weekly treatment. Identifi-
cation of patients who are likely to respond to arginase
therapy is a key challenge. The arginine recycling cascade
is composed at the cellular level of the enzymes ASS,
OTC and ASL, and expression determines cellular argin-
ine auxotrophism [6]. Despite ASS or OTC having vari-
able expression in a range of solid and haematological
tumours, no ASL negative tumour cells have been de-
scribed. Classically arginine depleting therapies such as
pegylated arginine deiminase or BCT-100 are most effect-
ive when one or more of the enzymes have low or absent
expression [8, 13]. Interestingly, BCT-100 also has activity
against tumours which express both ASS and OTC, unlike
ADI-PEG, suggesting differences in their modes of action
or other intracellular pathways are contributing to deter-
mine cell fate [7, 9, 10, 12].
The transcriptional profile (as demonstrated by the heat-
map in Fig. 1d) is completely different to that of a represen-
tative population of melanomas, suggesting that there may
be distinct changes in this patients’ melanoma. Analysis of
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the patient’s tumour and control melanomas highlighted
low ASS and OTC expression consistent with the paradigm
that the absence of these enzymes renders tumour cells sus-
ceptible to arginine deprivation. Thus, melanomas may be
broadly sensitive to arginine deprivation, and selection of
patients based on ASS and OTC expression could be
considered at screening in future clinical trials of arginase
therapy with BCT-100. Interestingly, BCT-100 has
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Fig. 1 Arginase therapy is effective against immunotherapy-resistant melanoma. a CT thorax and abdominal radiographs at screening, showing extensive
apical, pleural and diaphragmatic disease, in axial and coronal reconstructions and b complete remission in axial and coronal reconstructions. Radiographs
were reported according to RECIST criteria. c Volcano plot of differential expression between complete responder melanoma and melanoma cohort. Red
dots indicate significantly differential expression (BF > 10). Gene names shown. d Heatmap of top 30 differentially expressed genes via RNA-seq between
BCT-100 responsive melanoma (BCT-Mel, n= 2 repeats, red) and control cohort (consisting of melanoma cell lines MEWO, 501_MEL and eight primary cell
cultures from stage IV melanomas) as listed on the X-axis. e Expression of arginine pathway genes in patient and control samples, expressed relative to
GAPDH. f Representative immunohistochemistry of patient’s tumour showing background staining (top), ASS (1:5000, dilution - middle) and OTC (1:5000
dilution bottom). Positive control staining on a neuroblastoma tumour shown for comparison. g Expression of arginine pathway enzymes in 44 samples of
metastatic melanomas held with the R2: Genomics Analysis and Visualization Platform (http://r2.amc.nl)
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demonstrated preclinical activity against melanoma cancer
cells. Future translational studies on melanoma patients will
investigate the threshold of ASS and OTC expression, and
non-canonical pathways that could lead to resistance against
arginase therapy.
Immunotherapy, notably immune checkpoint inhibitors,
has heralded a sea-change in the management of adult
malignancies, particularly in melanoma. However, many
patients are still not cured even after addition of standard
chemotherapy drugs or small molecule inhibitors to treat-
ment regimens. Arginase therapy could see the advent of
metabolic treatments for melanoma, following the long-
standing success of targeting tumour metabolism in paedi-
atric malignancies with drugs such as PEG-asparaginase
and methotrexate. Importantly, the promising lack of tox-
icity of arginase therapy could allow this type of approach
to be used in patients with significant co-morbidities
which are frequently present in adult and elderly popula-
tions. In particular, BCT-100’s low toxicity profile has
allowed for long-term administration with continued effi-
cacy, compared to ADI-PEG or AEB1102 for which con-
cerns over immunogenicity that result in allergic reactions
or neutralising antibody development, or lack of activity
have limited their use [9, 10, 13]. Indeed in a phase I/II
trial of PEG-arginine deiminase in 31 patients with ad-
vanced, previously treated melanomas, no objective re-
sponses were seen and arginine depletion occurred only
transiently [14]. In a phase I trial of AEB1102 which in-
cluded nine patients with relapsed melanoma post im-
munotherapy with immune checkpoint inhibitors, the
best response achieved was in one patient with stable dis-
ease (7 progressive disease, 1 unknown) [15]. The case
also highlights the potential that initial priming of the im-
mune response with anti-CTLA-4/ PD-1 checkpoint in-
hibitor antibodies may work in concert with subsequent
BCT-100 in the setting of melanoma.
In conclusion, BCT-100 PEGylated recombinant human
arginase led to a sustained and well-tolerated complete re-
mission of a metastatic melanoma that failed prior im-
munotherapy, with the identification that tumour ASS
and OTC expression could help future patient selection.
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Availability of data and materials
RNA sequencing
RNA was derived from the FFPE melanoma sections via extraction with the
Qiagen RNEasy FFPE tissue kit. Extracted RNA was quantified using Qubit
flourimetry. Library preparation was performed using Illumina TruSeq mRNA
library preparation kit and sequenced on an Illumina NextSeq 500. A control
dataset was obtained from the Gene Expression Omnibus (accession no.
GSE20156) consisting of three replicates of the melanoma cell line MeWo,
the melanoma cell line 501Mel, the control leukaemia cell line K562 and
eight primary melanoma cell cultures from stage 4 tumours. Aligned BAM
files were processed using FeatureCounts, and then gene centric RPKM were
used to constructed a heatmap using sample and gene level unsupervised
hierarchical clustering using heatmap2. Data is shown in the figure.
Validation cohort
We analysed transcriptomic data from an additional n = 44 metastatic
melanoma patients held within the R2: Genomics Analysis and Visualization
Platform (http://r2.amc.nl). Patients were aged 30–92 years of age and
diagnosed with metastatic melanoma. Patients were followed after resection
of the metastatic lesion. Patients were treated with surgery (100%),
chemotherapy (32%), radiotherapy (24%) and immunotherapy (13%). Patients
were stage I (18%), II (29%), III (47%) or IV (3%) at initial presentation. Full
characteristics are reported here [16].
Immunohistochemistry
Paraffin-embedded tissue sections were deparaffinised and rehydrated. Antigen
retrieval was performed in 10 mM sodium citrate, 0.05% Tween 20 and pH 6.0
using a Tefal mini-compact steamer. Staining with anti-human argininosuccinate
synthase (ASS; Atlas) and anti-human ornithine transcarbamylase (OTC; Atlas) is
done using the Novolink Polymer Detection System (RE7280-K, Leica). Primary
antibody incubations were carried out overnight at 4 °C, and tissue sections
counterstained with haematoxylin and mounted in DPX (VWR). To assess
nonspecific staining, the samples were similarly treated, but in the absence of the
primary antibodies or rabbit IgG (Vector Labs Peterborough UK).
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